What is Michael F. Cola’s Phathom Pharmaceuticals share ownership after this RSU grant?

After receiving 24,122 Restricted Stock Units, Michael F. Cola is reported as directly holding 63,920 shares of Phathom Pharmaceuticals common stock. This figure reflects his position following the equity award, as disclosed in the Form 4 insider transaction filing.

Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Phathom Pharmaceuticals director Michael F. Cola received 24,122 Restricted Stock Units (RSUs) as an equity award. The grant was made under the company’s Non-Employee Director Compensation Program and is a compensation-related acquisition, not an open-market stock purchase.

The RSUs will vest 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting, as long as Cola continues serving on the board through that date. Each RSU converts into one share of common stock, bringing his reported direct holdings to 63,920 shares after the grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider COLA MICHAEL F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,122	$0.00	--

Holdings After Transaction: Common Stock — 63,920 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 24,122 units Grant price: $0.00 per RSU Shares after transaction: 63,920 shares +2 more

5 metrics

RSUs granted 24,122 units Restricted Stock Units granted on May 19, 2026

Grant price $0.00 per RSU Equity award under Non-Employee Director Compensation Program

Shares after transaction 63,920 shares Common stock directly held after RSU grant

Vesting trigger 1 year or next meeting 100% vests on first anniversary or next annual stockholder meeting

RSU-to-share ratio 1:1 Each RSU represents a right to one common share

Key Terms

Restricted Stock Units ("RSUs"), Non-Employee Director Compensation Program, annual meeting of the Issuer's stockholders

3 terms

Restricted Stock Units ("RSUs") financial

"The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-Employee Director Compensation Program financial

"The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program."

annual meeting of the Issuer's stockholders financial

"shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders"

Form 4 Insider Transactions: What Each Field Means →

05/21/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COLA MICHAEL F

(Last)

(First)

(Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK

NEW JERSEY

07932

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/19/2026		A		24,122⁽¹⁾	A	$0	63,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

	/s/ Anne Marie Cook, Attorney-in-Fact for Michael F. Cola	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Phathom Pharmaceuticals (PHAT) report for Michael F. Cola?

Phathom Pharmaceuticals reported that director Michael F. Cola received 24,122 Restricted Stock Units as an equity award. The grant is compensation under the Non-Employee Director Compensation Program, not an open-market share purchase or sale, and increases his direct reported holdings to 63,920 shares.

How many Phathom Pharmaceuticals RSUs were granted to director Michael F. Cola?

Michael F. Cola received 24,122 Restricted Stock Units from Phathom Pharmaceuticals. These RSUs were granted at no cash cost per unit and each unit represents a contingent right to receive one share of common stock upon vesting, subject to continued board service.

When do Michael F. Cola’s Phathom Pharmaceuticals RSUs vest?

The 24,122 RSUs granted to Michael F. Cola vest 100% on the earlier of the first anniversary of the May 19, 2026 grant date or the next annual stockholder meeting. Vesting requires his continued service on Phathom Pharmaceuticals’ board through that vesting date.

Is Michael F. Cola’s Phathom Pharmaceuticals RSU grant an open-market stock purchase?

The RSU grant to Michael F. Cola is not an open-market stock purchase. It is a compensation-related equity award under the Non-Employee Director Compensation Program, issued at zero cash price per unit and subject to vesting based on continued board service.